ATR · Aptargroup, Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Jul 31, 2026TL;DR. Aptar reported Q2 sales over $1 billion for the first time (up 6% reported, 1% core) with adjusted EPS of $1.42 (down 15% YoY) and 20.7% adjusted EBITDA margin (down from 22.6%) pressured by emergency medicine destocking, beauty/closures operational issues, and a delayed resin pass-through in beauty; Q3 adjusted EPS guidance of $1.45–$1.53 was reaffirmed.
- + Reported sales topped $1 billion for the first time, up 6% reported and 1% core, with all three segments posting core sales growth
- − Adjusted EPS of $1.42 declined 15% year-over-year at comparable FX due to emergency medicine decline, beauty/closures operational issues, higher D&A, and higher interest expense
- − Adjusted EBITDA margin compressed 190 bps to 20.7% from 22.6%, with all three segment margins declining year-over-year
- − Closures adjusted EBITDA margin fell 200 bps to 14.9% on new production line ramp-up and ongoing maintenance initiative
- − Adjusted effective tax rate rose to 23.7% from 20.0%, adding to EPS pressure
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ATR
this stock
Aptargroup, Inc.
|
$7.93B | +2.0% | +5.4% | 22.6 | 2.6% |
|
ISRG
Intuitive Surgical Inc
|
$137.70B | -30.6% | +20.5% | 44.8 | 2.2% |
|
BDX
Becton Dickinson & Co
|
$50.64B | — | +8.2% | — | 3.9% |
|
MDLN
Medline Inc.
|
$41.60B | -24.7% | +11.5% | — | 3.0% |
|
ALC
Alcon Inc
|
$32.76B | -17.5% | +10.5% | — | 3.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ATR | -0.3% | -6.4% | +2.0% | -5.5% | +2.0% |
| SPY | -0.3% | -0.1% | +20.1% | -0.7% | +11.7% |
| vs SPY | +0.0% | -6.3% | -18.1% | -4.8% | -9.7% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.